The therapeutic targeting of inhibitory checkpoint molecules against CTL-associated protein 4 (CTLA-4), PD-1, and PD-L1 have led to profound clinical responses and have revolutionized the landscape of cancer immunotherapy across multiple cancer types (9). The gene discussed is PDCD1; the disease is cancer.